JP2018531620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531620A5 JP2018531620A5 JP2018529689A JP2018529689A JP2018531620A5 JP 2018531620 A5 JP2018531620 A5 JP 2018531620A5 JP 2018529689 A JP2018529689 A JP 2018529689A JP 2018529689 A JP2018529689 A JP 2018529689A JP 2018531620 A5 JP2018531620 A5 JP 2018531620A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mutation
- nucleic acid
- determination
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 104
- 201000011510 cancer Diseases 0.000 claims description 95
- 230000035772 mutation Effects 0.000 claims description 81
- 150000007523 nucleic acids Chemical class 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 54
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 239000012472 biological sample Substances 0.000 claims description 31
- 108020004705 Codon Proteins 0.000 claims description 22
- 239000003471 mutagenic agent Substances 0.000 claims description 8
- 231100000707 mutagenic chemical Toxicity 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 claims description 7
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 claims description 7
- 230000003505 mutagenic effect Effects 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 claims description 3
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 claims description 2
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 230000011132 hemopoiesis Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000002703 mutagenesis Methods 0.000 claims description 2
- 231100000350 mutagenesis Toxicity 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000000875 corresponding effect Effects 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 5
- 229940122135 Deaminase inhibitor Drugs 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 1
- 102100040397 C->U-editing enzyme APOBEC-1 Human genes 0.000 description 1
- 102100038050 DNA dC->dU-editing enzyme APOBEC-3H Human genes 0.000 description 1
- 101710082737 DNA dC->dU-editing enzyme APOBEC-3H Proteins 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903456 | 2015-08-26 | ||
| AU2015903456A AU2015903456A0 (en) | 2015-08-26 | Methods of detecting cancer recurrence | |
| PCT/AU2016/050799 WO2017031551A1 (en) | 2015-08-26 | 2016-08-26 | Methods of detecting cancer recurrence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531620A JP2018531620A (ja) | 2018-11-01 |
| JP2018531620A5 true JP2018531620A5 (enExample) | 2019-10-03 |
| JP6850294B2 JP6850294B2 (ja) | 2021-03-31 |
Family
ID=58099416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529689A Active JP6850294B2 (ja) | 2015-08-26 | 2016-08-26 | 癌の再発を検出する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11225690B2 (enExample) |
| EP (1) | EP3341496B1 (enExample) |
| JP (1) | JP6850294B2 (enExample) |
| CN (2) | CN108603231B (enExample) |
| AU (1) | AU2016310415B2 (enExample) |
| ES (1) | ES2873841T3 (enExample) |
| WO (1) | WO2017031551A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6850294B2 (ja) | 2015-08-26 | 2021-03-31 | ジーエムディーエックス カンパニー プロプライエタリー リミテッド | 癌の再発を検出する方法 |
| US11875877B2 (en) | 2016-08-25 | 2024-01-16 | Nantomics, Llc | Immunotherapy markers and uses therefor |
| WO2019095017A1 (en) * | 2017-11-17 | 2019-05-23 | Gmdx Co Pty Ltd | Systems and methods for predicting the efficacy of cancer therapy |
| CN108796077B (zh) * | 2018-05-30 | 2021-11-09 | 朱运峰 | 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒 |
| EP4158070A4 (en) * | 2020-06-01 | 2025-05-07 | GMDx Co Pty Ltd | METHODS FOR PREDICTING CANCER PROGRESSION |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| WO2014066955A1 (en) * | 2012-11-05 | 2014-05-08 | Lindley Robyn Alice | Methods for determining the cause of somatic mutagenesis |
| JP6850294B2 (ja) | 2015-08-26 | 2021-03-31 | ジーエムディーエックス カンパニー プロプライエタリー リミテッド | 癌の再発を検出する方法 |
-
2016
- 2016-08-26 JP JP2018529689A patent/JP6850294B2/ja active Active
- 2016-08-26 EP EP16838136.6A patent/EP3341496B1/en active Active
- 2016-08-26 WO PCT/AU2016/050799 patent/WO2017031551A1/en not_active Ceased
- 2016-08-26 ES ES16838136T patent/ES2873841T3/es active Active
- 2016-08-26 US US15/754,983 patent/US11225690B2/en active Active
- 2016-08-26 CN CN201680062714.2A patent/CN108603231B/zh active Active
- 2016-08-26 CN CN202310693406.1A patent/CN116574809A/zh not_active Withdrawn
- 2016-08-26 AU AU2016310415A patent/AU2016310415B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liang et al. | Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy | |
| JP2018531620A5 (enExample) | ||
| Pstrąg et al. | Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates | |
| Edlundh-Rose et al. | NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing | |
| JP2010538609A5 (enExample) | ||
| JP2018518980A5 (enExample) | ||
| JP6850294B2 (ja) | 癌の再発を検出する方法 | |
| Salmaninejad et al. | Molecular characterization of KRAS, BRAF, and EGFR genes in cases with prostatic adenocarcinoma; reporting bioinformatics description and recurrent mutations | |
| Ranjbari et al. | BRAF mutations in Iranian patients with papillary thyroid carcinoma | |
| Gallegos-Arreola et al. | Pathophysiology of acute lymphoblastic leukemia | |
| Roy et al. | Genetics and epigenetics of breast cancer | |
| Hudler | Outlook on epigenetic therapeutic approaches for treatment of gastric cancer | |
| Wang et al. | EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients | |
| Li et al. | Evaluation of DNA repair gene XRCC1 polymorphism in prediction and prognosis of hepatocellular carcinoma risk | |
| Malicherova et al. | Detection of driver mutations in FFPE samples from patients with verified malignant melanoma. | |
| JP2022548993A (ja) | Ｄｎａメチル化異常を用いた免疫抗癌治療反応性予測方法 | |
| Gajjar et al. | ERCC1 expression in patients with colorectal cancer: a pilot study | |
| Strzelczyk et al. | Expression profiles of MGMT, p16, and APC genes in tumor and matching surgical margin from patients with oral squamous cell carcinoma | |
| CN113564250B (zh) | 头颈部癌症的生物标志物及其使用方法 | |
| US20230257823A1 (en) | Biomarkers for identifying patients at high risk of progressing from barrett's esophagus to esophageal adenocarcinoma | |
| Murtaza et al. | Identification of a novel mutation in codon 31 of Kirstein rat sarcoma viral oncogene homologue in colon cancer: another evidence of non-canonical mutational pathway. | |
| Jamil et al. | Association of EGFR gene polymorphism in head and neck cancer patients with tobacco and alcohol consuming habits | |
| Hama et al. | KRAS and MT-CO1 genes in colorectal cancer: a molecular investigation | |
| Sathiyamoorthy et al. | Study on PIK3CA gene mutations in oral squamous cell carcinoma among South Indian populations | |
| Kanwal et al. | Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population |